Referred to the House Committee on Energy and Commerce.
The bill amends the Federal Food, Drug, and Cosmetic Act to add a new supply-chain transparency subchapter for cosmetics. It defines terms (brand owner, supplier, nonfunctional constituent, etc.), requires suppliers to provide brand owners specified safety, composition, and testing information within 90 days of request, and directs the FDA to create and maintain a list of nonfunctional constituents known or reasonably expected to be present in cosmetics and ingredients.
Scope of disclosure and public transparency: liberals want stronger consumer-facing disclosure; conservatives worry about protecting proprietary formulas.
Relative to its intended legislative type, this bill is a substantive regulatory change that is reasonably specific in statutory duties, definitions, and timelines, but it omits important implementation, resourcing, and confidentiality safeguards that would be expected for comprehensive execution.
The bill amends the Federal Food, Drug, and Cosmetic Act to add a new supply-chain transparency subchapter for cosmetics.
It defines terms (brand owner, supplier, nonfunctional constituent, etc.), requires suppliers to provide brand owners specified safety, composition, and testing information within 90 days of request, and directs the FDA to create and maintain a list of nonfunctional constituents known or reasonably expected to be present in cosmetics and ingredients.
Suppliers must test for listed nonfunctional constituents within one year of their addition and provide certificates of analysis with levels, methods, detection limits, and heavy metal tests.
On substance the bill is a targeted regulatory reform grounded in consumer safety and contains procedural compromises (advisory committee, comment periods, phased deadlines) that help its manageability. Nonetheless, the combination of new testing and disclosure duties, tension with trade-secret protections for fragrance/formulations, potential for substantial compliance costs (especially for small suppliers), and preserved state-by-state variation make it a moderately challenging bill to enact without further negotiation or amendment. Absent additional incentives, funding provisions, or softened proprietary-disclosure rules, the measure faces meaningful industry resistance and legal/implementation questions that lower the probability of enactment.
Relative to its intended legislative type, this bill is a substantive regulatory change that is reasonably specific in statutory duties, definitions, and timelines, but it omits important implementation, resourcing, and confidentiality safeguards that would be expected for comprehensive execution.
Scope of disclosure and public transparency: liberals want stronger consumer-facing disclosure; conservatives worry about protecting proprietary formulas.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope of disclosure and public transparency: liberals want stronger consumer-facing disclosure; conservatives worry about protecting proprietary formulas.
Likely broadly supportive.
The bill increases transparency about ingredients, nonfunctional contaminants, heavy metals, and allergens; mandates testing and documentation; and gives FDA tools to trace adulterated or misbranded products.
Those outcomes align with public-health and environmental-protection priorities.
Generally favorable but pragmatic checks.
The bill addresses a clear information gap in cosmetics supply chains—helping brand owners and regulators ensure product safety—while preserving state authority.
A centrist would welcome transparency and traceability but worry about administrative burdens, timelines, civil-penalty size, and whether FDA has needed resources.
Skeptical or opposed on balance.
The bill expands FDA authority, creates new mandatory testing and recordkeeping requirements across the cosmetics supply chain, and imposes substantial civil penalties—steps seen as regulatory overreach that raise compliance costs.
While the preservation of state rights is positive, the overall approach increases federal oversight of businesses and may harm small suppliers, formulating labs, and retailers.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On substance the bill is a targeted regulatory reform grounded in consumer safety and contains procedural compromises (advisory committee, comment periods, phased deadlines) that help its manageability. Nonetheless, the combination of new testing and disclosure duties, tension with trade-secret protections for fragrance/formulations, potential for substantial compliance costs (especially for small suppliers), and preserved state-by-state variation make it a moderately challenging bill to enact without further negotiation or amendment. Absent additional incentives, funding provisions, or softened proprietary-disclosure rules, the measure faces meaningful industry resistance and legal/implementation questions that lower the probability of enactment.
The bill has not accumulated any surfaced votes yet.
Scope of disclosure and public transparency: liberals want stronger consumer-facing disclosure; conservatives worry about protecting propri…
On substance the bill is a targeted regulatory reform grounded in consumer safety and contains procedural compromises (advisory committee,…
Relative to its intended legislative type, this bill is a substantive regulatory change that is reasonably specific in statutory duties, definitions, and timelines, but it omits important implementation, resourcing, and…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.